FLT3 Primary Antibody
|Aliases||FLK2; STK1; CD135; FLK-2|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Purified recombinant fragment of human FLT3 (AA: 930-991) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|WB (Western Blot)||1/500 - 1/2000|
Contact us to order
Figure 1: Western blot analysis using FLT3 mAb against human FLT3 recombinant protein. (Expected MW is 32.6 kDa)
Figure 2: Immunohistochemical analysis of paraffin-embedded cervical cancer tissues using FLT3 mouse mAb with DAB staining.
Figure 3: Immunohistochemical analysis of paraffin-embedded liver cancer tissues using FLT3 mouse mAb with DAB staining.
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
|Description||This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. |
|References (references)||1. J Immunol. 2012 Oct 15;189(8):3822-30. |
2. Cancer. 2012 Dec 15;118(24):6110-7.